Everything below concerns FSFI endpoint. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
To qualify for protection under the FCA, the whistleblower must demonstrate that they were engaged in FCA-protected activity and that the employer knew their activity was protected under the FCA, which presents a challenge for whistleblowers who merely report regulatory violations. To be protected under the FCA, they must reasonably believe the regulatory noncompliance has or will amount to fraud against the government, and they must put the employer on notice that their protected activity relates to the filing of false or fraudulent claims. Laboratory workers who merely report CLIA violations without tying the issues to Medicare or Medicaid reimbursement are unlikely to receive FCA whistleblower protection. From 2004-2005, approximately 460 patients Maryland General Hospital were tested for Hepatitis C and HIV with invalid controls. Follow-up retesting was not possible as many patients were unreachable due to being homeless. The incident prompted CAP to add whistleblower protections. In September 2015, a Theranos employee emailed a complaint to the Centers for Medicare and Medicaid Services (CMS) outlining regulatory noncompliance, which led to the company's exposure as a fraud and subsequent downfall.
Extrapyramidal side effects such as: (which usually become apparent soon after therapy is begun or soon after an increase in dose is made) Muscle rigidity Hypokinesia Hyperkinesia Parkinsonism Tremor Akathisia Dystonia Dry mouth Constipation Hypersalivation – excessive salivation Blurred vision Diaphoresis – excessive sweating Nausea Dizziness Somnolence Restlessness Insomnia Overactivity Headache Nervousness Fatigue Myalgia Hyperprolactinemia and its complications such as: (acutely) Sexual dysfunction Amenorrhea – cessation of menstrual cycles Gynecomastia – enlargement of breast tissue in males Galactorrhea – the expulsion of breast milk that's not related to breastfeeding or pregnancy and if the hyperprolactinemia persists chronically, the following adverse effects may be seen: Reduced bone mineral density leading to osteoporosis (brittle bones) Infertility Dyspepsia – indigestion Abdominal pain Flatulence Nasal congestion Polyuria – passing more urine than usual Uncommon (0.1–1% incidence) adverse effects include
=== Approval === It is approved to treat complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CAP) in individuals 18 years and older. In the United Kingdom it is approved in adults and in children from the age of eight years for the treatment of complicated skin and soft tissue infections (excluding diabetic foot infections) and complicated intra-abdominal infections in situations where other alternative antibiotics are not suitable.
== Price fixing investigation == It is known whether this apparent price fixing is actively being investigated, but the United States Department of Justice Antitrust Division Spring Update 2021 notes: "The Division remains committed to rooting out illegal conduct that corrupts critical healthcare markets. That work is more important now than ever before. The Division has uncovered price-fixing, bid-rigging, and customer-allocation schemes in one of the most important markets for the health and wallets of American consumers: the generic drug industry. Indeed, nearly 90% of all prescriptions in the United States are filled with generic drugs."
=== Political grievances === Local authorities may also have become the focal point for more broad and abstract objections to the apartheid system. Boycott campaigns in 1983 and 1984 had sought to tie local grievances to the policies of the apartheid state, including the Koornhof reforms. On some accounts, attacks by protestors on the person and property of councillors and other state representatives was "a clear attack on apartheid symbols", while vigilantes' concern with rooting out collaborators reflected a similar concern with undermining the overall apartheid system. Some observers argued that, as the uprising continued, the strategies and aims of some participants changed, with many – particularly militant youth – setting their sights on the much larger goal of rendering the country "ungovernable" and, ultimately, that of dismantling apartheid through violence.
Sources: en.wikipedia.org
== History == The idea that the stomach produces a hormone to trigger acid secretion was first put forward by British physiologist John Sydney Edkins in 1905. Working with cats, he found that injecting extracts from the stomach lining causes an increase in acid production, and he called the substance responsible "gastrin". His theory was met with skepticism after histamine was discovered in 1910, as it had a similar effect on the stomach, leading many scientists to doubt whether gastrin was a separate hormone at all. The debate was largely settled in 1942, when Simon Komarov published research showing that a gastrin extract could stimulate acid secretion on its own, separate from histamine. Building on this work, Roderic Gregory and Hilda Tracy isolated the hormone in purified form in the early 1960s and identified two closely related versions, which they named gastrin I and gastrin II. Chemist George Kenner then determined the full amino acid sequence of both peptides, making gastrin the first gut hormone to have its complete structure worked out.
== External links == Ciliary+neurotrophic+factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P26441 (Ciliary neurotrophic factor) at the PDBe-KB.
As a result of this change tropical cyclones are 50% less likely to make landfall on Queensland, while the risk of a tropical cyclone is elevated for island nations like Niue, French Polynesia, Tonga, Tuvalu, and the Cook Islands.
Aspartate transaminase (AST) or aspartate aminotransferase, also known as AspAT/ASAT/AAT or (serum) glutamic oxaloacetic transaminase (GOT, SGOT), is a pyridoxal phosphate (PLP)-dependent transaminase enzyme (EC 2.6.1.1) that was first described by Arthur Karmen and colleagues in 1954. AST catalyzes the reversible transfer of an α-amino group between aspartate and glutamate and, as such, is an important enzyme in amino acid metabolism. AST is found in the liver, heart, skeletal muscle, kidneys, brain, red blood cells and gall bladder. Serum AST level, serum ALT (alanine transaminase) level, and their ratio (AST/ALT ratio) are commonly measured clinically as biomarkers for liver health. The tests are part of blood panels. The half-life of total AST in the circulation approximates 17 hours and, on average, 87 hours for mitochondrial AST. Aminotransferase is cleared by sinusoidal cells in the liver. Aspartate transaminase catalyzes the interconversion of the natural amino acid, L-aspartic acid and α-ketoglutaric acid to give oxaloacetic acid and L-glutamic acid.:
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.